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presented for the entire cohort. Univariate and multivariate 
subgroup analysis will be performed to identify possible 
prognostic factors using the log rank test and the Cox 
regression method, respectively. Rates of severe side effects 
and complication rates will be reported descriptively.  
Conclusions: This pooled analysis offers the opportunity to 
evaluate the efficacy and toxicity of a multimodal treatment 
approach including IORT, EBRT and gross total limb-sparing 
surgery in a large series of patients with extremity sarcoma 
treated in European expert centers and therefore may serve 
as a benchmark for other treatment approaches.  
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Purpose/Objective: Patients with locally advanced rectal 
cancer have a dismal prognosis. 
Materials and Methods: We investigated outcomes in 77 
consecutive patients with T4 tumors treated with 
preoperative chemoradiotherapy (CRT), surgery and IOERT. 
Results: Median follow-up was 62.8 months (range, 4-198). 5 
year Loco-regional control, disease-free survival and overall 
survival was 84%, 68% and 65%. 
Conclusions: Overall results after multimodality treatment of 
T4 are promising. Classification of risk factors for LRR would 
contributed to propose a prognostic index that could allow us 
to guide risk-adapted tailored treatment  
 
 
Poster Discussion: Dose modelling and planning  
 
 
PD-0523   
Fractionation-corrected doses with deformable registration 
as a tool for treatment plan comparison 
E. Boman1,2, L. Pickup3, M. Kapanen1,2, T. Kadir3 
1Tampere University Hospital, Department of Oncology, 
Tampere, Finland  
2Medical Imaging Center and Hospital Pharmacy, Medical 
Physics, Tampere, Finland  
3Mirada Medical Ltd., Oxford Centre for Innovation, Oxford, 
United Kingdom  
 
Purpose/Objective: In radiotherapy treatment planning for 
patients with tumor relapse, a number of factors must be 
taken into account, such as prior treatments to the area, 
total dose to critical organs, and dose-per-fraction effects 
within the patient volume. The aim of this study was to 
develop a simple tool to explore 3D biological dose 
summation with non-rigid fusion, and to demonstrate its 
importance in treatment planning. 
Materials and Methods: Fine-scale deformable image 
registration was carried out in Mirada RTx™ (Mirada Medical 
Ltd., Oxford, UK), and inspected for plausibility using 
registration QC tools (see Fig 1C). The deformation grids 
were used to transform dose distributions from prior 
treatments into the space of the current target CT. Thus, 
given the number of fractions in each treatment plan, the 
fractional doses for every voxel in the new planning CT 
volume were calculated for each treatment. 
The software used the linear-quadratic (LQ) model for 
equivalence calculations, and doses were expressed as 2Gy 
equivalent dose (EQD2), which were summed voxel-wise to 
give the EQD2 for the total treatment. The interface was 
designed to allow users to specify different alpha/beta-ratios 
per structure on the planning CT, and also to enter a healing 
parameter to down-scale effects of past treatments. 
An illustrative H&N case is presented. A malignancy on the 
left side of the tongue received standard three dose level 
simultaneously integrated boost (SIB) treatment 
(33x2/1.82/1.64Gy at 66/60/54Gy) with a seven field 6MV 
IMRT technique. The planning CT and PTVs are shown in Fig 
1A. Two years after the primary treatment, the patient 
experienced a relapse on the right side, and a 25x2Gy 
treatment was planned for the new PTV (Fig 1B). Even after 
positioning the patient to minimize the difference between 
CTs, the large tissue deformations due to tumor mass and 
neck rigidity presented a challenging registration problem. 
Total doses (in EQD2) to critical organs were investigated, 
using alpha/beta-ratios of 2.1Gy for the medulla, and 3Gy for 
other organs.  
 
 
 
